CTRI/2018/10/016125
Not yet recruiting
Phase 3
A Comparative, Two arm, Randomized, Double blind, Parallel Group, Vehicle Controlled Clinical Study to Evaluate Efficacy and Safety of Ivermectin Lotion 0.5% w/w for the Treatment of Pediculus humanus capitis (head lice) Infestation
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
- Sponsor
- Ajanta Pharma Ltd
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects meeting all of the following criteria will be recruited for the trial:
- •1\.Healthy males, non\-pregnant females and children of age \>\=6 months to \<\=65 years (both inclusive) will be enrolled.
- •2\.Subjects must have an active head lice infestation of atleast three live lice and/or viable nits. (Viability of nits to be determined by using magnifying lens at a distance of less than 0\.6 cm/6 mm from the scalp).
- •3\.Following application and rinsing of the test article, subject agrees not to shampoo, wash, or rinse their hair or scalp until the 24 hour post treatment evaluation has been completed.
- •4\.Subject agrees not to cut or chemically treat their hair while participating in the study.
- •5\.Subject and/or parent/guardian agree that the subject will not use any other form of lice treatment during the duration of the study.
- •6\.Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures. Caregivers who are willing to sign Informed Consent agreement for children of age \<7 years. Children of age \>\=7 years who are willing to sign a childâ??s assent form.
Exclusion Criteria
- •Subjects will be excluded if ANY of the following conditions apply:
- •1\.Female subjects who are pregnant or lactating or planning to become pregnant during the study period. Females who are not ready to use acceptable contraceptive methods during the course of study.
- •2\.Scalp condition that could make it difficult to evaluate the extent and severity of an infestation or that would present a problem in the evaluation of response to therapy (e.g. psoriatic scalp lesions, extensive seborrheic dermatitis).
- •3\.Treatment for head lice (OTC, home remedy and/or prescription drugs) in the last 7 days.
- •4\.Subject who used any hair dye, bleaches, hair straightening or permanent wave solution on the hair within 14 days of randomization.
- •5\.Known history of irritation or sensitivity to pediculicides or hair care products.
- •6\.Subjects with known allergy or hypersensitivity to Ivermectin or any component of the test product.
- •7\.Any condition or illness that may compromise the objective of the protocol.
- •8\.Subject receiving any other treatment which may interfere with the study results.
- •9\.Participation in a previous investigational drug study within the past 30 days.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A Clinical Trial to evaluate Efficacy and Safety of Bilastine Tablet 20 mg Vs. Levocetirizine Tablet 5 mg for the Treatment of Allergic RhinoconjunctivitisHealth Condition 1: null- Allergic RhinoconjunctivitisHealth Condition 2: H108- Other conjunctivitisCTRI/2017/06/008889Ajanta Pharma Ltd214
Completed
Phase 2
Comparative Study to assess efficacy and safety of Mycobacterium W. in Combination with Standard Therapy versus Standard Therapy Alone in treatment of Sepsis.Health Condition 1: null- Sepsis due to Gram Negative InfectionHealth Condition 2: A419- Sepsis, unspecified organismCTRI/2015/07/005961Cadila Pharmaceuticals Limited202
Completed
Phase 3
A Clinical Study to Evaluate Efficacy, Safety and Tolerability of Iguratimod Tablets Vs. Methotrexate Tablets for the treatment of Active Rheumatoid Arthritis.Health Condition 1: null- Active Rheumatoid ArthritisHealth Condition 2: E888- Other specified metabolic disordersCTRI/2017/07/009079Ajanta Pharma Ltd244
Completed
Phase 3
A Clinical trial to check the effect, Safety and Tolerability of Ripasudil Hydrochloride Hydrate Eye Drops 0.4% w/v Vs Timolol Maleate Eye Drops 0.5% w/v in patients with Ocular Hypertension / GlaucomaHealth Condition 1: null- Ocular Hypertension/GlaucomaHealth Condition 2: H408- Other glaucomaCTRI/2018/04/013091Ajanta Pharma Ltd217
Completed
Phase 3
A study of Netarsudil Ophthalmic Solution 0.02% w/v Vs Timolol Maleate Eye Drops 0.5% w/v in treatment of elevated intraocular pressure in patient with open angle glaucoma or ocular hypertension.Health Condition 1: H401- Open-angle glaucomaCTRI/2020/01/022619Ajanta Pharma Ltd197